Cardiovascular risks of antiretroviral therapies

Kristin Mondy, Pablo Tebas

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

The use of highly active antiretroviral therapy (HAART) has resulted in sustained reductions in mortality from HIV infection. In recent years, HAART has also been associated with metabolic complications that may increase patients' cardiovascular disease risk. Recent studies have begun to support a more complex interaction between HAART, HIV infection itself, and other traditional social and immunologic factors that may predispose patients to premature cardiovascular disease. Substantial progress has been made in the development of newer antiretroviral therapies that have a better metabolic profile with respect to dyslipidemia, hyperglycemia, and lipodystrophy. Optimal selection of metabolically neutral antiretroviral therapies, together with aggressive management of other modifiable coronary risk factors, may improve cardiovascular disease risk in the long term.

Original languageEnglish (US)
Pages (from-to)141-155
Number of pages15
JournalAnnual Review of Medicine
Volume58
DOIs
StatePublished - 2007

Keywords

  • HIV therapy
  • Metabolic complications

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Cardiovascular risks of antiretroviral therapies'. Together they form a unique fingerprint.

  • Cite this